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co-payment groups. Analysis used the auto-regressive integrated moving-average 
model in STATA 9.0. RESULTS: The overall number of outpatient visits signiﬁ cantly 
decreased after policy implementation due to a reduction in the number of patients 
using outpatient facilities, but total costs of care remained unchanged. The policy had 
its greatest impact on the number of visits to regional and local community hospitals 
(secondary), but had no inﬂ uence on those the medical centres (tertiary). Medical 
utilisation in physician clinics (primary) decreased due to an audit of reimbursement 
declarations. Overall, the policy failed to encourage referrals from primary care to 
higher tiers. CONCLUSIONS: Further research needs to explore how patients’ out-
of-pocket payment affects medical utilisation and which forces (not susceptible to co-
payment) act in tertiary facilities. It also needs to investigate, whether the reduction 
in outpatient numbers was due to an affordability barrier to accessing essential care, 
with a potentially negative impact on the region’s health.
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OBJECTIVES: To deter non-essential visits and encourage initial contact in primary
care, Taiwan’s National Health Insurance’s (NHI) implemented a differential co-
payment policy on July 15, 2005. A previous study has examined the impact of this
policy on medical utilization and total cost to NHI using a regional reimbursement 
dataset. This study aimed to explore the impact of this policy on outpatient co-
payment and prescription patterns across different co-payment groups and tiers of 
medical facilities. METHODS: A segmented time-series analysis on regional weekly 
outpatient medical claims (January 2004 to July 2006). Outcome variables for co-
payment and prescription patterns were stratiﬁ ed by tiers of medical facilities and co-
payment groups. Analysis used the auto-regressive integrated moving-average model 
in STATA 9.0. RESULTS: Despite the decrease in outpatient visits, the overall co-
payment to patients increased by 1.2% after policy implementation and also increased
in most medical facilities (4.8% to 17.9%). Number of general prescriptions decreased 
across different medical facilities; the average cost and duration per general prescrip-
tion decreased in medical centers and regional hospitals. The number of continuous 
prescriptions did not change, except for non-signiﬁ cant decreases in medical centers
and regional hospitals. There was an increase in the number of continuous prescrip-
tions dispensed in pharmacies (7.0%). CONCLUSIONS: The police signiﬁ cantly 
increased patients’ out-of-pocket payment for outpatient visits. In response to the 
policy, physicians might prescribe more expensive drugs and extend prescription dura-
tion to help patients get the most beneﬁ t from the co-payment, and physician in
medical centers are more likely to prescribe continuous prescriptions for patients with
stable chronic diseases. Further research needs to identify vulnerable subgroups in 
obtaining necessary treatment, and to explore the impacts of cost-saving strategies on 
patients’ quality of medical care.
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OBJECTIVES: We sought to evaluate the impact of pharmacy cost-containment policy 
actions by state Medicaid programs on cost-related underuse of medicine, controlling
for concurrent non-pharmacy cost-containment policy actions and socio-environmen-
tal differences among states. METHODS: We used the data from the 2003 Community
Tracking Study (CTS) household survey, and linked them with the census demographic 
data and the cost containment policy actions based upon 50 States Surveys on state 
Medicaid spending growth and cost containment policy actions by the Kaiser Family
Foundation in 2003. A cross-sectional study was performed to evaluate the impact of 
policy actions, by comparing Medicaid beneﬁ ciaries to non-Medicaid-pharmacy-cost-
containment-action-eligible residents. The outcome measures included: patients do not 
receive needed medical care, patients cannot afford needed prescriptions, patients
postpone needed medical care, and patients worry about the medical care cost. The 
outcomes were analyzed using logit model, with prior authorization, generic drugs
required, copayment method, step therapy of fail-ﬁ rst requirement, limit on number 
of prescriptions and number of reﬁ lls per month, preferred drug list, over the counter
coverage, and prescription drug payment practices (payment and purchasing policies) 
as predictors. Additionally, non-pharmacy cost-containment policy actions, patients’
demographics and states’ socio-environmental variables were controlled. RESULTS:
On average, each state has implemented 6.5% pharmacy cost containment policy
actions in 2003. Only the worrying about costs was statistically signiﬁ cantly associated
with individual pharmacy cost-containment policy action; however, such signiﬁ cance
disappeared after other concurrent pharmacy cost-containment policy actions were
controlled for. When the total number of pharmacy cost-containment policy actions
was entered in the regression instead of individual policy action, each incremental 
policy action was associated with 14% increase in odds ratio for unmet medical needs
(p  0.003), and 5% increase in odds ratio for postponing medical needs (p  0.02). 
CONCLUSIONS: There was variable impact of pharmacy cost-containment policy
actions when assessed concurrently, and collectively.
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OBJECTIVES: Although cost-effectiveness analysis allows efﬁ cient decisions about the 
use of existing technologies (static efﬁ ciency) it has been argued that it will disincen-
tivise the development of innovative technologies (dynamic efﬁ ciency). These concerns
have also been raised about the report by the UK Ofﬁ ce of Fair Trading which recom-
mended that the price of pharmaceuticals should be based on their cost-effectiveness. 
We aim to establish whether decisions based on cost-effectiveness necessarily under-
mine incentives for the development of pharmaceuticals. METHODS: The arguments
put forward as to why cost-effectiveness decisions might undermine incentives for
innovation are examined and are used to consider the implications of the type of 
value-based pricing which has been proposed in the UK. RESULTS: The argument 
depends on whether the purpose of health care is to improve population health or to 
maximise welfare (consumer and producer surplus). If it is the former, then achieving
static and dynamic efﬁ ciency requires a clear and predictable signal of value (cost-
effectiveness). The private sector can then choose to invest in developments which it 
believes will be cost-effective and provide a satisfactory return on investment. Manu-
facturers should be allowed to appropriate some share of the surplus (monopoly rent) 
to incentivise investment in R&D. However, they should not take it all. The public 
sector subsidises research and development in many ways. Therefore, even if society
was unconcerned about who beneﬁ ts from innovation it would not be efﬁ cient to
allow full appropriation. In other markets where innovation is protected, society 
simply offers monopoly rent during patent protection but does not allow full appro-
priation by, for example, facilitating perfect price discrimination. CONCLUSIONS:
The argument that decisions about the use and price of a technology based on cost-
effectiveness will undermine the incentives for R&D is misplaced if the objective is to 
improve population health given a ﬁ xed budget constraint.
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OBJECTIVES: The Orphan Drug Act (ODA) was developed in 1983 to stimulate new
drug development to treat rare diseases. The purpose of this analysis was to review
the drug development with orphan drug status and to describe utilization of orphan 
drugs in the Medicaid program. METHODS: A literature review about orphan drug 
approvals was conducted through search engine like PubMed, as well as government
and industry Internet websites. Nationwide Medicaid pharmacy data extracted from
the Center for Medicare & Medicaid Services were analyzed from 1991 to 2007 
regarding quarterly prescriptions, reimbursements, and cost per prescription for
selected orphan drugs. Based on utilization patterns, two categories of orphan drugs
were studied, including traditional ones with little use (like antizole, fabrazyme, 
respigam, myozyme, and panhematin) and non-traditional ones with wide usages (like
paclitaxel, epoetin alfa, and imatinib mesylate). RESULTS: Since 1983, over 1700
drugs have been designated as having orphan status and 325 drugs have marketing
approval to treat orphan diseases, focusing on oncology, metabolic and endocrine 
disorders, and hematology. From Medicaid pharmacy data, there was very little use
for antizole, respigam, myozyme, and other traditional orphan drugs, such as fabra-
zyme from 15 in 2003 to the peak of 375 in 2006. By contrast, non-traditional orphan 
drug like epoetin alfa prescriptions increased from 17,282 in 1991 to the peak of 
824,485 in 2005, and imatinib mesylate prescriptions increased from 3,877 in 2001
to the peak of 20,323 in 2005. Fabrazyme cost per prescription started with $22,367
in 2003 and decreased to $5,558 in 2006. Other expensive orphan drugs included
myozyme, panhematin, imatinib mesylate, and ritumximab ranging from $3,000 to 
$10,000 per prescription. CONCLUSIONS: ODA has made a signiﬁ cant impact on
drug development for rare diseases. Non-traditional orphan drugs with dramatic 
increased utilization and spending were observed, which might require safety surveil-
lance and appropriate utilization review.
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OBJECTIVES: The pharmaceutical industry serves societal needs by bringing innova-
tive products and therapies to market. However, innovation does not guarantee 
market longevity. Consequently, some products will be evaluated and considered for 
market discontinuation. The purpose of this study was to identify drug market dis-
continuations, provide reasons for discontinuation, and characterize discontinued 
products by application type. METHODS: Data were derived from the FDA databases 
“Approved Drug Products” and the “Approved Drug Products with Therapeutic 
Equivalence Evaluations,” Federal Register, and Medline. Market discontinuations 
were classiﬁ ed by approval types (New Drug Application -NDA and Abbreviated New 
Drug Application-ANDA) and by reasons for discontinuation (safety, efﬁ cacy and 
